
Eva Kempers/LinkedIn
Jan 29, 2025, 21:39
Occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease
Sebastian Szmit, Consultant at the Maria Sklodowska-Curie National Research Institute of Oncology, shared an article by Eva Kempers et al. on LinkedIn:
“Next great study published by the research group associated with the SERENITY trial supported by European Commission.
I am proud to be part of this scientific adventure!”
Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease.
Authors: Eva Kempers, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 6, 2025, 09:03
Mar 6, 2025, 08:52
Mar 6, 2025, 08:15
Mar 6, 2025, 08:03